Pale melanomas can hide behind albinism genes

Melanoma is most often recognised by colour — the dark, irregular patch that prompts a dermatologist to look closer. For people with albinism, that visual signal may not appear at all.

A study reported by Medical Xpress found that melanomas arising in people with albinism can present without the pigmentation typically used as a primary diagnostic marker. The research identified a mechanism by which albinism-associated gene variants suppress melanin production even within tumour cells, leaving the lesions pale and, as a result, harder to distinguish from surrounding skin.

What the research found

The study's authors reported that the same genetic pathways that reduce pigment in the skin of people with albinism also affect melanocytes when they become malignant. The finding, the researchers said, means that standard pigment-based visual screening criteria may be unreliable for this population.

Pale or amelanotic melanomas — those with little or no colour — are already known to be more frequently missed and diagnosed at later stages than pigmented tumours, according to existing dermatological literature. The research suggests people with albinism may face a structurally elevated version of that same risk.

The study's authors called for clinicians examining patients with albinism to rely more heavily on lesion morphology, texture, and border irregularity rather than colour change alone. Dermoscopy, which allows detailed examination of skin structure beneath the surface, was identified as a more appropriate tool for this group.

What this means for sun protection and screening

People with albinism already carry a significantly higher lifetime risk of skin cancer than the general population, owing to the near-absence of melanin that ordinarily absorbs ultraviolet radiation. Organisations including the Albinism Fellowship and Under the Same Sun have long documented the burden of UV-related skin disease within the community, particularly in equatorial regions where sun exposure is intense and specialist dermatological care is limited.

This research adds a second layer to that risk: not only are skin cancers more likely to develop, they may also be less likely to be caught early using conventional methods.

The practical consequence, as the researchers framed it, is that dermatologists and primary care clinicians need specific guidance when screening people with albinism — guidance that accounts for the altered appearance of malignancy in low-pigment skin.

Access to that level of specialist care remains uneven. In many of the countries where the albinism community is largest, routine dermoscopy is not standard practice, and training in amelanotic presentations is limited even in well-resourced settings.

The researchers did not publish specific incidence figures in the summary reviewed, but the directional finding is clear: current screening tools were largely designed around pigmented presentations, and people with albinism fall outside that assumption.